Progress in Sensors for Monitoring Reinforcement Corrosion in Reinforced Concrete Structures-A Review.

Non-destructive monitoring methods and continuous monitoring systems based on them are crucial elements of modern systems for the management and maintenance of assets which include reinforced concrete structures. The purpose of our study was to summarise the data on the most common sensors and systems for the non-destructive monitoring of reinforced concrete structures developed over the past 20 years. We considered systems based on electrochemical (potentiometry, methods related to polarisation) and physical (electromagnetic and ultrasonic waves, piezoelectric effect, thermography) examination methods. Special focus is devoted to the existing sensors and the results obtained using these sensors, as well as the advantages and disadvantages of their setups or other equipment used. The review considers earlier approaches and available commercial products, as well as relatively new sensors which are currently being tested.

Low-Dose vs. Standard-Dose Intravenous Alteplase in Bridging Therapy Among Patients With Acute Ischemic Stroke: Experience From a Stroke Center in Vietnam.

Background: To date, the role of bridging intravenous thrombolysis before mechanical thrombectomy (MTE) is controversial but still recommended in eligible patients. Different doses of intravenous alteplase have been used for treating patients with acute ischemic stroke from large-vessel occlusion (LVO-AIS) in Asia, largely due to variations in the risks for intracerebral hemorrhage (ICH) and treatment affordability. Uncertainty exists over the potential benefits of treating low-dose alteplase, as opposed to standard-dose alteplase, prior to MTE among patients with LVO-AIS. Aim: The aim of the study was to compare outcomes of low- vs. standard-dose of bridging intravenous alteplase before MTE among LVO-AIS patients. Methods: We performed a retrospective analysis of LVO-AIS patients who were treated with either 0.6 mg/kg or 0.9 mg/kg alteplase prior to MTE at a stroke center in Northern Vietnam. Multivariable logistic regression models, accounting for potential confounding factors including comorbidities and clinical factors (e.g., stroke severity), were used to compare the outcomes between the two groups. Our primary outcome was functional independence at 90 days following stroke (modified Rankin score; mRS ≤ 2). Secondary outcomes included any ICH incidence, early neurological improvement, recanalization rate, and 90-day mortality. Results: We analyzed data of 107 patients receiving bridging therapy, including 73 with low-dose and 34 with standard-dose alteplase before MTE. There were no statistically significant differences between the two groups in functional independence at 90 days (adjusted OR 1.02, 95% CI 0.29-3.52) after accounting for potential confounding factors. Compared to the standard-dose group, patients with low-dose alteplase before MTE had similar rates of successful recanalization, early neurological improvement, 90-day mortality, and ICH complications. Conclusion: In the present study, patients with low-dose alteplase before MTE were found to achieve comparable clinical outcomes compared to those receiving standard-dose alteplase bridging with MTE. The findings suggest potential benefits of low-dose alteplase in bridging therapy for Asian populations, but this needs to be confirmed by further clinical trials.

Studying on some predictors of hematoma enlargement occured in patients with hypertensive intracerebral hemorrhage

69 patients with hypertensive intracerebral hemorrhage (HICH) admitted within 24 hours of stroke onset. 14/69 patients (20.3%) with enlarged hematomas after the first CT was performed during 30 minutes at admission and the second within 24-36 hours of admission (33%). Multivariate analyses revealed that the following three factors were independently associated with hematoma enlargement: the time from stroke onset, prothrombin ratio, the shape of hematoma. Hematoma enlargement was an independent factor increasing the mortality rate in the HICH patients